GenIbet is a Portuguese biologics CDMO acquired by Recipharm (now operating as Recipharm Advanced Bio), specializing in advanced therapy medicinal products (ATMPs) including xRNA therapies, viral vectors, microbial and live biotherapeutic products, and recombinant proteins. The company provides end-to-end preclinical development and commercial manufacturing capabilities for biotherapeutics. GenIbet holds FDA registration and has been inspected by the FDA.
Advanced therapy CDM, xRNA therapies, viral vectors, live biotherapeutic products, recombinant proteins
1 site worldwide
No certifications on file yet.
No reviews available yet.
No documents available.